Pharmaceutical company Mayne Pharma says it expects first-half pre-tax earnings to triple this financial year due to strong sales of its women’s health products, sending its shares up 24.4 per cent.

Investors betting the Adelaide-based drugmaker was showing signs of stabilising its performance after five years of volatility sent the company’s shares to their highest level since May last year to $5.82.